Literature DB >> 29796070

Retrospective analysis of cancer patients admitted to a tertiary centre with suspected neutropenic sepsis: Are C-reactive protein and neutrophil count useful prognostic biomarkers?

Thomas Wilson1, Tim Cooksley1, Steven Churchill1, John Radford1, Paul Dark2.   

Abstract

Historically, neutropenic sepsis has been associated with high mortality rates. However, there has been limited research into cancer patients admitted with suspected sepsis who are found to be non-neutropenic. C-reactive protein has been shown to be raised in cancer patients for reasons other than infection and there have been limited studies to look as its utility as a prognostic biomarker in suspected sepsis in this population. This study looked at 749 patients admitted to a tertiary cancer centre between January 2015 and February 2016 with suspected sepsis. The neutrophil count and C-reactive protein level was taken in all these patients on admission and at 72 h and compared to the primary outcome of 30-day all-cause mortality rates and hospital length of stay. There were 49 patients who died within 30 days (6.5%). Patients who died were found to have both higher neutrophil counts and C-reactive protein level on admission and at 72 h compared to survivors. Prolonged grade 4 neutropenia was shown to have higher mortality rates. There was only weak correlation between either neutrophil counts or C-reactive protein level and length of hospital stay. This study suggests that higher C-reactive protein level and neutrophil counts and prolonged grade 4 neutropenia are associated with higher mortality rates in cancer patients admitted with suspected sepsis and have utility as prognostic biomarkers in this population.

Entities:  

Keywords:  Antibiotics; C-reactive protein; cancer; neutropenic sepsis; neutrophil

Year:  2017        PMID: 29796070      PMCID: PMC5956692          DOI: 10.1177/1751143717741248

Source DB:  PubMed          Journal:  J Intensive Care Soc        ISSN: 1751-1437


  23 in total

1.  Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.

Authors:  Regis G Rosa; Luciano Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Emergency oncology: development, current position and future direction in the USA and UK.

Authors:  Tim Cooksley; Terry Rice
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

3.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

4.  Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?

Authors:  William Shomali; Ray Hachem; Anne-Marie Chaftari; Ying Jiang; Ramez Bahu; Joseph Jabbour; Sammy Raad; Munirah Al Shuaibi; Iba Al Wohoush; Issam Raad
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

5.  Ambulatory Outpatient Management of patients with low risk febrile neutropaenia.

Authors:  Tim Cooksley; Mark Holland; Jean Klastersky
Journal:  Acute Med       Date:  2015

Review 6.  Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis.

Authors:  Chun-Wei Wu; Jiunn-Yih Wu; Chun-Kuei Chen; Shiau-Ling Huang; Shou-Chien Hsu; Meng-Tse Gabriel Lee; Shy-Shin Chang; Chien-Chang Lee
Journal:  Support Care Cancer       Date:  2015-02-21       Impact factor: 3.603

7.  A nurse-led protocol improves the time to first dose intravenous antibiotics in septic patients post chemotherapy.

Authors:  Graeme Mattison; Matthew Bilney; Phil Haji-Michael; Tim Cooksley
Journal:  Support Care Cancer       Date:  2016-07-25       Impact factor: 3.603

8.  Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial.

Authors:  Stella Sala Soares Lima; Vandack Nobre; Roberta Maia de Castro Romanelli; Wanessa Trindade Clemente; Henrique Neves da Silva Bittencourt; Ana Catarina Mourão Melo; Luciana Caetano Botelho Salomão; José Carlos Serufo
Journal:  Ann Hematol       Date:  2016-04-27       Impact factor: 3.673

9.  Time to antibiotics and outcomes in cancer patients with febrile neutropenia.

Authors:  Thomas Perron; Mohamed Emara; Shahid Ahmed
Journal:  BMC Health Serv Res       Date:  2014-04-10       Impact factor: 2.655

10.  Factors associated with hospital length of stay among cancer patients with febrile neutropenia.

Authors:  Regis G Rosa; Luciano Z Goldani
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more
  1 in total

1.  Prognostic Factors Predicting Poor Outcome in Cancer Patients with Febrile Neutropenia in the Emergency Department: Usefulness of qSOFA.

Authors:  Seung Jae Lee; Ji Hye Kim; Seung Baik Han; Jin Hui Paik; Areum Durey
Journal:  J Oncol       Date:  2018-10-11       Impact factor: 4.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.